Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 770371 in Compensated Cirrhosis Due to MASH
NCT06675929Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Liver cirrhosis (LC) comparing BI 770371 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jan 2025; status: completed.
02
Drugs
BI 770371
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06675929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675929.